September 10, 2024
SAN DIEGO — Combination therapy with osimertinib and savolitinib could become a novel first-line treatment option for patients with de novo MET-aberrant, EGFR-mutated advanced non–small cell […]
September 10, 2024
TOPLINE: Patients with early-onset colorectal cancer (CRC) living in rural and impoverished areas face a significantly higher risk of dying from CRC. METHODOLOGY: Previous research has […]
September 10, 2024
HOUSTON — Bruton’s tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the treatment of chronic lymphocytic leukemia (CLL). But should patients take a […]
September 9, 2024
HOUSTON — A new analysis hints that there may be a benefit from aspirin for hospitalized patients with leukemia. In a preliminary study, researchers found that […]
September 9, 2024
TOPLINE: Racial and ethnic minority groups, particularly Hispanic/Latinx and Black patients, remain underrepresented in immune checkpoint inhibitor (ICI) cancer trials, although recent years have shown an […]
September 9, 2024
SAN DIEGO — An analysis comparing patient-level data from two recent phase 3 trials demonstrated an approximately 40% reduction in the risk for non–small cell lung […]
September 9, 2024
(Reuters) -Relay Therapeutics said on Monday interim data from an early-stage study of its combination drug for breast cancer showed it meaningfully extended the time patients […]
September 8, 2024
First-line treatment with ivonescimab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients with PD-L1-positive advanced […]
September 6, 2024
Pancreatic cancer remains one of the deadliest cancers. When the disease is caught earlier, the 5-year survival rates hover around 44%, but once the cancer metastasizes, […]